{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:19:29Z","timestamp":1790241569044,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jdcr.2022.08.028","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:03:35Z","timestamp":1661630615000},"page":"25-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream"],"prefix":"10.1016","volume":"29","author":[{"given":"Shannon","family":"Nugent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Coromilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph C.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdcr.2022.08.028_bib1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamadermatol.2018.5635","article-title":"Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes","volume":"155","author":"Hashemi","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2022.08.028_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.det.2015.03.003","article-title":"Necrobiosis lipoidica","volume":"33","author":"Sibbald","year":"2015","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jdcr.2022.08.028_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ajd.12420","article-title":"Pentoxifylline: an effective therapy for necrobiosis lipoidica","volume":"58","author":"Wee","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2022.08.028_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2022.08.028_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/jamadermatol.2018.0756","article-title":"Improvement in ulcerative necrobiosis lipoidica after Janus kinase-inhibitor therapy for polycythemia vera","volume":"154","author":"Lee","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2022.08.028_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.01.001","article-title":"Remission of necrobiosis lipoidica diabeticorum with a JAK1\/2 inhibitor: a case report","volume":"47","author":"Barbet-Massin","year":"2021","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.jdcr.2022.08.028_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdcr.2019.11.016","article-title":"Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2022.08.028_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jdcr.2022.08.028_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ijd.15960","article-title":"Ulcerated necrobiosis lipoidica successfully treated with tofacitinib","volume":"61","author":"Janssen","year":"2022","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.08.028_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:22Z","timestamp":1762475122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622003848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":10,"alternative-id":["S2352512622003848"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.028","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}